Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr;128(4):624-626.
doi: 10.1016/j.ophtha.2020.08.026. Epub 2020 Sep 1.

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

M Teresa Magone  1 , Iris R Hartley  2 , Edmond Fitzgibbon  3 , Rachel Bishop  3 , Mike Arango  3 , Susan Moran  4 , Roo Vold  4 , Jaydira Del Rivero  5 , Karen Pozo  6 , Jamie Streit  6 , Kelly L Roszko  6 , Michael T Collins  6 , Rachel I Gafni  6
Affiliations
Clinical Trial

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

M Teresa Magone et al. Ophthalmology. 2021 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 2.
Figure 2.
A, Photograph of the right cornea of patient number 4 showing basement membrane haze grade 1 (white arrows) localized to the anterior Basement membrane (BM) (inset) with clear stroma underneath. The patient also had mild punctate keratopathy (center) and deep epitheliopathy with a demarcation line (black horizontal arrow), which appeared 87 days after starting infigratinib and only resolved after discontinuation of the study drug as seen in B. B, Same eye of patient number 4 at 1 month after discontinuation of infigratinib. The demarcation line resolved, but permanent nasal anterior basement membrane haze remained (arrow). C, Photograph of cornea of patient number 1 showing small areas of opacification (arrows main photograph) localized to the deep corneal stroma and Descemet’s membrane (DM) on cross-beam view (left inset white arrows) and high-resolution OCT (right inset white arrows). The patient did not have overlying corneal edema or anterior chamber inflammation. This grade 2 keratitis adverse event (AE) occurred 64 days after starting infigratinib and led to drug interruption. D, Photograph of cornea of patient number 1 on study day 140 showing grade 2 symptomatic infigratinib-related epitheliopathy causing blurry vision. Symptomatic epitheliopathy occurred on average 91 ± 53 days (mean ± standard deviation) after starting infigratinib in patients with healthy baseline examination results.
See this image and copyright information in PMC

Comment in

References

    1. Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052–16074. - PMC - PubMed
    1. Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018;36:276–282. - PMC - PubMed
    1. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res 2004;79:677–688. - PubMed
    1. Medeiros CS, Marino GK, Santhiago MR, Wilson SE. The corneal basement membranes and stromal fibrosis. Investig Ophthalmol Vis Sci 2018;59:4044–4053. - PMC - PubMed
    1. Dolivo DM, Larson SA, Dominko T. Fibroblast growth factor 2 as an antifibrotic: antagonism of myofibroblast differentiation and suppression of pro-fibrotic gene expression. Cytokine Growth Factor Rev 2017;38:49–58. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources